Ovid Therapeutics Inc (OVID) - News Archive

Ovid Therapeutics Reveals Promising Pre-Clinical Outcomes for OV329: Absence of Accumulation in Animal Retinas Contrasts with Vigabatrin NEW YORK, Sept. 26, 2024 - Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceuti...

In the pharmaceutical industry, companies must continually navigate challenges while striving for growth and profitability. This article explores the recent developments surrounding Ovid Therapeutics Inc. (NASDAQ: OVID)...

CSIMarket.com aims to provide and evidence-based information on the latest advancements in the field of pharmacology. In line with this , this article presents recent findings published in eNeuro, a peer-reviewed, open-...

Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to advancing treatments for rare epilepsies and brain conditions, in collaboration with Graviton Bioscience Corporation, a clinical-stage biot...

Ovid Therapeutics Provides Insight into Takeda s Phase 3 Topline Study Results for Soticlestat in Rare Epileptic SyndromesIn a promising development in the field of rare epileptic syndromes, Ovid Therapeutics Inc. has s...

In an exciting development for the biopharmaceutical industry, Ovid Therapeutics Inc. and Ligand Pharmaceuticals Incorporated have announced a groundbreaking $30 million agreement that will extend Ovid s financial runwa...